Ardelyx (ARDX) Accounts Payables (2013 - 2026)
Ardelyx posted quarterly Accounts Payables of $28.2 million for Q1 2026, up 105.47% year-on-year from $13.7 million in Q1 2025, and up 46.58% on a QoQ basis from $19.2 million in Q4 2025.
Ardelyx (ARDX) has 14 years of Accounts Payables data on file, last reported at $28.2 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 105.47% year-over-year to $28.2 million; the trailing twelve-month figure through Mar 2026 stood at $28.2 million (up 105.47% YoY), and the FY2025 full-year result was $19.2 million, up 20.22% from the prior year.
- Accounts Payables for Q1 2026 stood at $28.2 million, up from $19.2 million in the prior quarter.
- Across five years, Accounts Payables topped out at $28.2 million in Q1 2026 and bottomed at $3.1 million in Q3 2022.
- The 5-year median for Accounts Payables is $11.1 million (2023), against an average of $12.9 million.
- Peak annual rise in Accounts Payables reached 153.89% in 2022, while the deepest fall reached 26.98% in 2022.
- A 5-year view of Accounts Payables shows it stood at $10.9 million in 2022, then grew by 2.57% to $11.1 million in 2023, then jumped by 43.65% to $16.0 million in 2024, then increased by 20.22% to $19.2 million in 2025, then jumped by 46.58% to $28.2 million in 2026.
- The last three Accounts Payables figures came in at $28.2 million (Q1 2026), $19.2 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn | 28.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.20 Mn |
| Dec 31, 2025 | 19.24 Mn |
| Sep 30, 2025 | 18.39 Mn |
| Jun 30, 2025 | 21.69 Mn |
| Mar 31, 2025 | 13.72 Mn |
| Dec 31, 2024 | 16.00 Mn |
| Sep 30, 2024 | 15.82 Mn |
| Jun 30, 2024 | 10.88 Mn |
| Mar 31, 2024 | 17.28 Mn |
| Dec 31, 2023 | 11.14 Mn |
| Sep 30, 2023 | 7.74 Mn |
| Jun 30, 2023 | 5.29 Mn |
| Mar 31, 2023 | 10.51 Mn |
| Dec 31, 2022 | 10.86 Mn |
| Sep 30, 2022 | 3.11 Mn |
| Jun 30, 2022 | 4.29 Mn |
| Mar 31, 2022 | 5.03 Mn |
| Dec 31, 2021 | 4.28 Mn |
| Sep 30, 2021 | 4.26 Mn |
| Jun 30, 2021 | 2.59 Mn |
| Mar 31, 2021 | 5.38 Mn |
| Dec 31, 2020 | 5.63 Mn |
| Sep 30, 2020 | 2.49 Mn |
| Jun 30, 2020 | 4.21 Mn |
| Mar 31, 2020 | 1.01 Mn |
| Dec 31, 2019 | 2.19 Mn |
| Sep 30, 2019 | 2.69 Mn |
| Jun 30, 2019 | 1.26 Mn |
| Mar 31, 2019 | 2.93 Mn |
| Dec 31, 2018 | 1.15 Mn |
| Sep 30, 2018 | 2.27 Mn |
| Jun 30, 2018 | 3.17 Mn |
| Mar 31, 2018 | 1.76 Mn |
| Dec 31, 2017 | 3.93 Mn |
| Sep 30, 2017 | 1.72 Mn |
| Jun 30, 2017 | 4.71 Mn |
| Mar 31, 2017 | 5.89 Mn |
| Dec 31, 2016 | 5.64 Mn |
| Sep 30, 2016 | 6.30 Mn |
| Jun 30, 2016 | 4.75 Mn |
| Mar 31, 2016 | 4.88 Mn |
| Dec 31, 2015 | 2.78 Mn |
| Sep 30, 2015 | 2.71 Mn |
| Jun 30, 2015 | 2.68 Mn |
| Mar 31, 2015 | 2.54 Mn |
| Dec 31, 2014 | 3.13 Mn |
| Sep 30, 2014 | 1.02 Mn |
| Jun 30, 2014 | 2.31 Mn |
| Dec 31, 2013 | 2.28 Mn |